Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

18.96 +0.47 (+2.54%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Get In Now. 7 Stocks That Are Set to Soar. ↗

April 13, 2023

While it’s always difficult to determine which stocks to buy might break out imminently, speculators should watch these ideas.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023 ↗

April 13, 2023

Via Benzinga

Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

March 24, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs...

Via FinancialNewsMedia

Relay Therapeutics's Return On Capital Employed Overview ↗

March 01, 2023

Via Benzinga

Relay Therapeutics Earnings Preview ↗

February 22, 2023

Via Benzinga

Evogene Offers An Excellent Risk/Reward Ratio ↗

March 21, 2023

We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their...

Via Talk Markets

Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR

March 06, 2023

Relay Therapeutics to host conference call following AACR presentation

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

March 01, 2023

From Relay Therapeutics, Inc.

Via GlobeNewswire

5 Analysts Have This to Say About Relay Therapeutics ↗

September 30, 2022

Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings within the last quarter:

Via Benzinga

Expert Ratings for Relay Therapeutics ↗

September 30, 2022

Within the last quarter, Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings:

Via Benzinga

4 Analysts Have This to Say About Relay Therapeutics ↗

September 14, 2022

Within the last quarter, Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings:

Via Benzinga

Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

February 23, 2023

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

February 16, 2023

From Relay Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗

February 03, 2023

Via Benzinga

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day

February 02, 2023

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

November 07, 2022

From Relay Therapeutics, Inc.

Via GlobeNewswire

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗

December 19, 2022

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

Via Benzinga

Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

November 03, 2022

From Relay Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For November 3, 2022 ↗

November 03, 2022

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

Via Benzinga

Relay Therapeutics's Earnings Outlook ↗

November 02, 2022

Relay Therapeutics (NASDAQ:RLAY) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Relay...

Via Benzinga

Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights

October 27, 2022

From Relay Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2022 ↗

September 30, 2022

Upgrades

Via Benzinga

7 Unknown Biotech Stocks That Could Rocket in 2023 ↗

September 23, 2022

Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.

Via InvestorPlace

Wells Fargo Slashes Price Target On This Stock By Over 71%, Also Check Out Other Major PT Changes Here ↗

September 14, 2022

Wells Fargo cut the price target on Cabaletta Bio, Inc. (NASDAQ: CABA) from $14 to $4. Wells Fargo analyst Derek Archila maintained the stock with an Overweight rating. Cabaletta Bio shares gained 0.9%...

Via Benzinga

Tesla, Meta, NVIDIA And Other Big Losers From Tuesday ↗

September 14, 2022

U.S. stocks closed sharply lower with the Nasdaq Composite dipping more than 5% on Tuesday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 13, 2022

Via Benzinga

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday ↗

September 14, 2022

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...

Via Benzinga

Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.